NYMOX PHARMACEUTICAL recorded a $4.275475 million net loss for 2025, or $0.05 per share, while Research and Development spending fell to $1.481965 million. The company expects R&D costs to decline further as U.S. BPH trial activity is reduced, but future Revenue depends on candidates passing trials and reaching the market.

Key Highlights

  • Nymox reported zero sales and zero total revenue for 2025.
  • Research and development spending fell to $1.481965 million from $3.280532 million.
  • The company had 102,040,140 shares outstanding at December 31, 2025.

NYMOX PHARMACEUTICAL CORP (OTC: NYMXF) recorded a net loss of $4.275475 million for the year ended December 31, 2025, equal to $0.05 per basic and diluted share. The 2025 loss was $4.275475 million compared with $4.491797 million in 2024, while the per-share result was $0.05 in both years. Nymox generated no revenue from sales of goods during either year. Nymox expects research and development expenditures to decline further as U.S. BPH trial activity is reduced, pending evaluation of the data.

2025 Loss And Per-Share Result

The company’s loss from Operating Activities was $3.676757 million in 2025, compared with $4.283129 million in 2024. The basic and diluted loss per share was -$0.05. Nymox reported a weighted average of 96,040,140 common shares during the year, while 102,040,140 shares were outstanding at December 31, 2025. Total Assets stood at $0.575942 million at year-end, compared with $0.653752 million at the end of 2024. Total Equity was negative $9.305703 million.

Research Spending Falls

Research and development expenditures declined to $1.481965 million from $3.280532 million in 2024. The spending mainly supported the advancement of Nymox’s BPH and prostate cancer candidate NX-1207 through clinical trials, along with work related to efficacy and regulatory compliance before a potential launch. The 2025 reduction included a $0.891769 million decrease in laboratory service expenditures, a $0.110964 million decrease in stock-based compensation and a $0.789253 million decrease in professional fees. General and administrative expenses were $2.195 million in 2025. Marketing expenditures were zero for 2024 and 2023, according to the comparative disclosures.

Revenue Depends On Trials

Nymox said its current priority is developing therapeutic candidates and moving them through Clinical Trials and regulatory review. Sales growth is expected to become a greater priority when candidates reach the marketing stage. The company expects research and development spending to fall further because of reduced U.S. BPH trial activity, subject to evaluation of the data. Nymox said it cannot set out the nature, timing or estimated costs required to complete its research projects because of their early development stage and related uncertainty.

Approval And Development Risks

Nymox identified the possibility that required regulatory approvals for commercialization may not be received. It also cited risks inherent in field trials, uncertainty about the nature and extent of regulatory requirements, and uncertainty surrounding its early-stage research and development projects. The company said the timing and cost of completing its projects cannot be estimated because of those factors. It also said a drug candidate that demonstrates efficacy can take seven years or more to obtain regulatory approval.